摘要
[目的]探讨吉西他滨联合顺铂方案(GP)及异长春花碱联合顺铂方案(NP)治疗晚期非小细胞肺癌的疗效及毒副反应。[方法]晚期非小细胞肺癌35例采用GP方案,38例采用NP方案,治疗2个周期后评价疗效及毒副反应。[结果]总有效率GP组为45.8%,NP组为52.6%;中位生存期分别为10.5和9.9个月,两组比较无显著性差异(P>0.05)。主要的毒副反应为血液毒性。[结论]GP和NP方案治疗晚期非小细胞肺癌疗效肯定且相似,毒副反应可以耐受。
To evaluate the efficacy and toxicity of vinorelbine combined with cisplatin(NP regimen) versus gemcitabine combined with cisplatin(GP regimen) in the treatment of advanced non-small-cell lung cancer(NSCLC). Thirty-five cases with advanced NSCLC received GP regimen, and thirty-eight cases with advanced NSCLC received NP regimen. The efficacy and toxicity were evaluated after two cycles. The overall response rates of GP regimen group and NP regimen group were 45.8% and 52.6%, respectively, and the median survivals were 10.5 and 9.9 months, respectively. There was no significant difference between two groups in response rate and median survival. The major toxicity was hematological toxicity. [Conclusion] The GP and NP regimen for advanced NSCLC were both effective and their effects were similar. The toxicity was tolerable.
出处
《肿瘤学杂志》
CAS
2005年第1期13-15,共3页
Journal of Chinese Oncology
关键词
吉西他滨
异长春花碱
顺铂
癌
非小细胞肺
gemcitabine
navelbine
cisplatin
carcinoma, non-small-cell lung
